FDA has agreed to expand the labeling for Edwards Lifesciences Corp.’s Sapien transcatheter aortic valve replacement, currently the only FDA-approved TAVR system, based largely on data from a post-market registry, the agency announced Sept. 23.
The new indication represents between 10 and 20 percent of TAVR patients, but the approval is even more significant due to the “message that FDA is sending in that they are looking at ways of post-market surveillance,” said Michael Mack, a cardiothoracic surgeon who chairs the steering committee of the
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?